Evolution of oseltamivir resistance mutations in influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6398-6405

  Pizzorno, Andrés ^a   Abed, Yacine ^a   Plante, Pier Luc ^a   Carbonneau, Julie ^a   Baz, Mariana ^a,b   Hamelin, Marie Ève ^a   Corbeil, Jacques ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; MUTANT PROTEIN; OSELTAMIVIR; RECOMBINANT PROTEIN; SIALIDASE; ANTIVIRUS AGENT; ENZYME INHIBITOR; VIRAL PROTEIN; VIRUS HEMAGGLUTININ;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; IC50; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); LUNG HOMOGENATE; MDCK CELL LINE; MICROBIAL POPULATION DYNAMICS; MOLECULAR CLONING; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; VIRUS CHARACTERIZATION; VIRUS MUTATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; DOG; DRUG EFFECTS; GENETIC SELECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MICROBIAL SENSITIVITY TEST; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; ORTHOMYXOVIRIDAE INFECTIONS; SEQUENCE ANALYSIS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; EVOLUTION, MOLECULAR; HEMAGGLUTININS, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RECOMBINANT PROTEINS; SELECTION, GENETIC; SEQUENCE ANALYSIS, RNA; VIRAL PROTEINS;

EID: 84908610840     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02956-14     Document Type: Article

References (39)

1. Colman PM, Hoyne PA, Lawrence MC. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980.
2. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB. 1998. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:3234-3241.
3. McKimm-Breschkin JL. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47:1-17. http://dx.doi.org/10.1016/S0166-3542(00)00103-0.
4. Gubareva LV. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199-203. http://dx.doi.org/10.1016/j.virusres.2004.02.034.
5. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. http://dx.doi.org/10.1016/S0140-6736(04)16934-1.
6. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
7. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G. 2002. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J. Infect. Dis. 186:1074-1080. http://dx.doi.org/10.1086/344237.
8. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Mersosn J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
9. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. 2006. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 193:765-772. http://dx.doi.org/10.1086/500464.
10. Ghedin E, Holmes EC, Depasse JV, Pinilla LT, Fitch A, Hamelin ME, Papenburg J, Boivin G. 2012. Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J. Infect. Dis. 206:1504-1511. http://dx.doi.org/10.1093/infdis/jis571.
11. Abed Y, Goyette N, Boivin G. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9:577-581.
12. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. 2009. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 361:2296-2297. http://dx.doi.org/10.1056/NEJMc0910060.
13. Roussy JF, Abed Y, Bouhy X, Boivin G. 2013. Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis. J. Clin. Microbiol. 51:4234-4236. http://dx.doi.org/10.1128/JCM.02659-13.
14. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31. http://dx.doi.org/10.1093/infdis/jiq010.
15. Boisvert S, Laviolette F, Corbeil J. 2010. Ray: simultaneous assembly of reads from a mix of high-throughput sequencing technologies. J. Comput. Biol. 17:1519-1533. http://dx.doi.org/10.1089/cmb.2009.0238.
16. Boisvert S, Raymond F, Godzaridis E, Laviolette F, Corbeil J. 2012. Ray Meta: scalable de novo metagenome assembly and profiling. Genome Biol. 13:R122. http://dx.doi.org/10.1186/gb-2012-13-12-r122.
17. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43:491-498. http://dx.doi.org/10.1038/ng.806.
18. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754-1760. http://dx.doi.org/10.1093/bioinformatics/btp324.
19. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976.
20. Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G. 2012. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob. Agents Chemother. 56:1208-1214. http://dx.doi.org/10.1128/AAC.05994-11.
21. World Health Organization. 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly. Epidemiol. Rec. 87:369-374.
22. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561. http://dx.doi.org/10.1086/508777.
23. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764. http://dx.doi.org/10.1086/500465.
24. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275. http://dx.doi.org/10.1126/science.1187816.
25. Abed Y, Pizzorno A, Bouhy X, Boivin G. 2011. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog. 7:e1002431. http://dx.doi.org/10.1371/journal.ppat .1002431.
26. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N. 2011. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N. Engl. J. Med. 365:2541-2542. http://dx.doi.org/10.1056/NEJMc 1111078.
27. Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP. 2012. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill. 17(36):pii20266. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId20266.
28. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi.org/10.1038/4371108a.
29. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
30. Abed Y, Pizzorno A, Bouhy X, Rheaume C, Boivin G. 2014. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J. Virol. 88:1652-1658. http://dx.doi.org/10.1128/JVI .02681-13.
31. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332. http://dx.doi.org/10.1002/prot.340140302.
32. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
33. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin. Infect. Dis. 51:983-984. http://dx.doi.org/10.1086/656439.
34. van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van Amerongen G, Schutten M, Kuiken T, Osterhaus AD, Fouchier RA, Boucher CA, Herfst S. 2011. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog. 7:e1002276. http://dx.doi.org/10.1371/journal.ppat .1002276.
35. Huang L, Cao Y, Zhou J, Qin K, Zhu W, Zhu Y, Yang L, Wang D, Wei H, Shu Y. 2014. A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance. Antimicrob. Agents Chemother. 58:1639-1645. http://dx.doi.org/10.1128/AAC.01848-13.
36. Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. 2014. Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob. Agents Chemother. 58:2718-2730. http://dx.doi.org/10.1128/AAC.02628-13.
37. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. http://dx.doi.org/10.1001/jama.297.13.1435.
38. Samson M, Pizzorno A, Abed Y, Boivin G. 2013. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 98:174-185. http://dx.doi.org/10.1016/j.antiviral.2013.03.014.
39. Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS. 2013. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio 4(4):e00396-13. http://dx.doi.org/10.1128/mBio .00396-13.